CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
LIQBIOPSENS aims to develop a diagnostic platform for the rapid detection of circulating tumor DNA and associated mutations in colorectal cancer. It combines advanced technologies to provide reliable, cost-effective, and user-friendly testing from blood samples.
The overall aim of LIQBIOPSENS project is the further development and validation in real settings of a novel diagnostic platform for the early and fast detection of ctDNA and their KRAS and BRAF mutations associated to colorectal cancer through blood samples.
The main features of LIQBIOPSENS are: reliability (detection rates vary from 95–100 %), low-cost (40-50 € per sample analysis), sensitivity (in the zM range), multiplexing capabilities (analysis of 27 KRAS and BRAF mutations simultaneously)…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
United Kingdom, EDINBOURGH
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Spain, GRANADA
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
FOUNDATION FOR RESEARCH AND TECHNOLOGYHELLAS
Greece, Irakleio
Type: Research institute
Activity type: Research Organisations
SME: No
Spain, Sevilla
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
